KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) EBT Margin (2016 - 2025)

Historic EBT Margin for NovoCure (NVCR) over the last 12 years, with Q3 2025 value amounting to 17.96%.

  • NovoCure's EBT Margin fell 40400.0% to 17.96% in Q3 2025 from the same period last year, while for Sep 2025 it was 23.43%, marking a year-over-year decrease of 36200.0%. This contributed to the annual value of 21.67% for FY2024, which is 159700.0% up from last year.
  • NovoCure's EBT Margin amounted to 17.96% in Q3 2025, which was down 40400.0% from 22.03% recorded in Q2 2025.
  • In the past 5 years, NovoCure's EBT Margin registered a high of 1.83% during Q1 2022, and its lowest value of 42.76% during Q2 2023.
  • In the last 5 years, NovoCure's EBT Margin had a median value of 19.2% in 2021 and averaged 20.92%.
  • As far as peak fluctuations go, NovoCure's EBT Margin crashed by -399800bps in 2023, and later surged by 276500bps in 2024.
  • Over the past 5 years, NovoCure's EBT Margin (Quarter) stood at 19.2% in 2021, then crashed by -32bps to 25.35% in 2022, then dropped by -14bps to 28.8% in 2023, then decreased by -19bps to 34.23% in 2024, then soared by 48bps to 17.96% in 2025.
  • Its last three reported values are 17.96% in Q3 2025, 22.03% for Q2 2025, and 19.55% during Q1 2025.